tiprankstipranks
Trending News
More News >

Verve Therapeutics price target raised to $39 from $32 at Canaccord

Canaccord raised the firm’s price target on Verve Therapeutics (VERV) to $39 from $32 and keeps a Buy rating on the shares. The firm said Verve’s initial Ph1b data for VERVE-102 knocked it out of the park on both safety and efficacy and accomplished everything it sought to do, and more. Canaccord increased our POS for the program from 50% to 70% and noted the company will report updated data including higher dose data, at a major medical meeting in 2H25.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue